Related Experiment Video

Updated: Aug 29, 2026

Reconstitution Of β-catenin Degradation In Xenopus Egg Extract
09:41

Reconstitution Of β-catenin Degradation In Xenopus Egg Extract

Published on: June 17, 2014

Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex

Maina Lepourcelet1, Ying-Nan P Chen, Dennis S France

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

Cancer Cell
|January 30, 2004
PubMed

Insights

Researchers identified natural compounds that disrupt the T cell factor (Tcf)/beta-catenin interaction, a key pathway in cancer. These compounds show potential for developing targeted cancer therapies by blocking this critical signaling pathway.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Key molecular lesions in cancers activate beta-catenin-dependent transcription of T cell factor (Tcf)-dependent genes.
  • Disrupting this oncogenic signaling pathway offers a strategy for rational cancer therapy.

Purpose of the Study:

  • To identify novel compounds that inhibit the protein-protein interaction between Tcf4 and beta-catenin.
  • To establish a standard for mechanism-based activity of small molecule inhibitors targeting this pathogenic interaction.

Main Methods:

  • Screening of natural compound libraries using a high-throughput immunoenzymatic assay.
  • Validation of compound activity through in vitro assays assessing Tcf/beta-catenin complex disruption.
  • Evaluation of cellular effects, including reporter gene activation, gene expression, and cell proliferation.

Main Results:

  • Selected natural compounds effectively disrupted Tcf/beta-catenin complexes in vitro.
  • These compounds antagonized beta-catenin-dependent activities, such as reporter gene activation, c-myc and cyclin D1 expression, and cell proliferation.
  • Compounds also inhibited Xenopus embryonic dorsal axis duplication, a model for beta-catenin signaling.

Conclusions:

  • The identified compounds meet criteria for inhibiting the Tcf/beta-catenin interaction.
  • These findings provide a foundation for developing targeted therapies against cancers driven by this pathway.
  • The study establishes a benchmark for evaluating small molecule inhibitors of this critical protein-protein interaction.

More Related Videos

The Soft Agar Colony Formation Assay08:01

The Soft Agar Colony Formation Assay

Published on: October 27, 2014

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Related Concept Videos

Catenins01:23

Catenins

Catenins are characterized by multiple binding domains and dynamic structures that allow them to function as linker proteins in cell junction complexes. All catenins, except α-catenin, contain a characteristic protein sequence called the armadillo repeat and are therefore also called armadillo proteins.
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the adherens...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...